An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Did you know that many vehicles and households today use alternative fuels instead of traditional…
Perplexity has launched a new AI powered assistant called Personal Computer. This is designed to…
Did you know that millions of homes around the world depend on a clean and…
Canara Bank has announced a revision in its Marginal Cost of Funds Based Lending Rate…
South Indian Bank has launched the new EPF payment service. This is in collaboration with…
The Honorable President of India Droupadi Murmu has addressed the inaugural session of the Global…